Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
MK-3118 is as an orally active new antifungal in the early stage of clinical development that inhibits the biosynthesis of β-(1,3)-glucan. We evaluated the in vitro activity of this compound against wild-type and echinocandin-resistant (ER) isolates containing mutations in the FKS gene(s) of Candida spp. and Aspergillus spp. MK-3118 demonstrated enhanced efficacy for most C. albicans and C. glabrata ER isolates relative to caspofungin, with decreased MICs and half-maximal inhibitory concentrations (IC 50 s).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“They alter the integrity of the fungal cell wall via the inhibition of the synthesis of the -(1,3)-glucan, its major component (2).”
BackgroundResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Self-citationGarcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Self-citationGarcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256 · cited 1×
“fumigatus (1 WT strain and 1 fks mutant strain), as described previously (18, 19).”
MethodSelf-citationA Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus
Rocha, E. M. F., Garcia-Effron, G., Park, S., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00917-07 · Cited by 141
Self-citationPfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
Self-citation
Cited by
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“niger, A terreus, cryptic species [130], and azole-resistant strains [108, 109, 127].”
BackgroundLarkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395
Stan, D., Enciu, A.-M., Mateescu, A. L., Ion, A. C., Brezeanu, A. C., Stan, D., & Tanase, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.723233 · Cited by 269
Metadata
- Authors
- Jiménez-Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-02
- Volume
- 58
- Issue
- 2
- Pages
- 1248-1251
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2016292914
- Cited by
- 122
- References
- 7
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates. https://app.cochat.ai/papers/10.1128/aac.02145-13
- The paper
- Jiménez-Ortigosa, C., Paderu, P., Motyl, M. R., & Perlin, D. S. (2014). Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02145-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.